[go: up one dir, main page]

BR9812565A - Amino terminalmente truncado rantes como antagonistas da quimiocina - Google Patents

Amino terminalmente truncado rantes como antagonistas da quimiocina

Info

Publication number
BR9812565A
BR9812565A BR9812565-6A BR9812565A BR9812565A BR 9812565 A BR9812565 A BR 9812565A BR 9812565 A BR9812565 A BR 9812565A BR 9812565 A BR9812565 A BR 9812565A
Authority
BR
Brazil
Prior art keywords
terminally truncated
rantes
truncated amino
chemokine
chemokine antagonists
Prior art date
Application number
BR9812565-6A
Other languages
English (en)
Inventor
Paul Proost
Sofie Struyf
Damme Jo Van
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9812565(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR9812565A publication Critical patent/BR9812565A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"AMINO TERMINALMENTE TRUNCADO RANTES COMO ANTAGONISTAS DA QUIMIOCINA"<D>. A presente invenção refere-se a amino terminalmente truncado RANTES, carecendo de aminoácidos de terminal NH~ 2~ correspondendo aos resíduos de aminoácido 1,1-2,1-3 ou 1-4 do RANTES de ocorrência natural e tendo atividade antagonística da quimiocina, assim como seq³ências de cDNA codificando os mesmos, seu uso em terapia e/ou diagnose de doenças, nas quais é necessária atividade antagonística dos efeitos da quimiocina, e composições farmacêuticas compreendendo os mesmos.
BR9812565-6A 1997-09-29 1998-09-28 Amino terminalmente truncado rantes como antagonistas da quimiocina BR9812565A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97116863A EP0906954A1 (en) 1997-09-29 1997-09-29 Amino-terminal truncated c-c chemokines as chemokine antagonist
EP97122471A EP0905240A1 (en) 1997-09-29 1997-12-19 Amino-terminally truncated c-c chemokines as chemokine antagonists
EP98104216A EP0905241A1 (en) 1997-09-29 1998-03-10 Amino-terminally truncated c-c chemokines as chemokine antagonists
PCT/EP1998/006143 WO1999016877A1 (en) 1997-09-29 1998-09-28 Amino-terminally truncated rantes as chemokine antagonists

Publications (1)

Publication Number Publication Date
BR9812565A true BR9812565A (pt) 2000-08-01

Family

ID=8227408

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9812565-6A BR9812565A (pt) 1997-09-29 1998-09-28 Amino terminalmente truncado rantes como antagonistas da quimiocina
BR9812394-7A BR9812394A (pt) 1997-09-29 1998-09-28 Amino terminalmente truncado mcp-2 como antagonistas da quimiocina

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9812394-7A BR9812394A (pt) 1997-09-29 1998-09-28 Amino terminalmente truncado mcp-2 como antagonistas da quimiocina

Country Status (28)

Country Link
US (5) US6977071B2 (pt)
EP (6) EP0906954A1 (pt)
JP (2) JP4230659B2 (pt)
KR (2) KR100560275B1 (pt)
CN (3) CN1145693C (pt)
AR (2) AR013528A1 (pt)
AT (3) ATE368742T1 (pt)
AU (2) AU750341B2 (pt)
BG (2) BG64679B1 (pt)
BR (2) BR9812565A (pt)
CA (2) CA2304827A1 (pt)
CY (1) CY1110927T1 (pt)
CZ (2) CZ299478B6 (pt)
DE (3) DE69823218T2 (pt)
DK (3) DK1021541T3 (pt)
EA (2) EA003940B1 (pt)
EE (2) EE200000151A (pt)
ES (3) ES2218860T3 (pt)
HU (2) HU226414B1 (pt)
IL (2) IL135352A (pt)
NO (2) NO20001584D0 (pt)
NZ (3) NZ503234A (pt)
PL (2) PL197569B1 (pt)
PT (3) PT1439231E (pt)
SK (2) SK286439B6 (pt)
UA (2) UA73081C2 (pt)
WO (2) WO1999016876A1 (pt)
ZA (2) ZA988676B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
AU1616499A (en) 1997-12-01 1999-06-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chemokine variants and methods of use
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
ATE339504T1 (de) * 1999-10-25 2006-10-15 Pharis Biotec Gmbh Prozessiertes menschliches chemokin phc-1
EP1167527A1 (en) * 2000-06-22 2002-01-02 Euroscreen S.A. Processed human chemokines PHC-1 and PHC-2
AU2505601A (en) * 1999-11-15 2001-05-30 Wolf-Georg Forssmann Novel use of hcc-2
CA2316405A1 (en) * 2000-05-26 2001-11-26 Ian Clark-Lewis Modulation of inflammation by protease products
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) * 2001-03-28 2002-10-02 Rega Inst For Medical Res Truncating chemokines using dipeptidyl peptidase IV
WO2003051921A1 (en) 2001-12-17 2003-06-26 Applied Research Systems Ars Holding N.V. Chemokine mutants acting as chemokine antagonists
WO2004104216A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
DE102005049637A1 (de) * 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
JP5624884B2 (ja) 2007-08-02 2014-11-12 ノビミューンエスアー 抗ｒａｎｔｅｓ抗体およびその使用の方法
WO2011097567A1 (en) * 2010-02-08 2011-08-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Rantes multiplexed assay, rantes variants related to disease, and rantes variants related to enzymatice activity
EP2545174B1 (en) 2010-03-11 2015-11-11 Health Research, Inc. Methods and compositions containing fc fusion proteins for enhancing immune responses
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
WO2019229615A1 (en) 2018-05-28 2019-12-05 Université De Genève Methods of inhibiting cerebral inflammation
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311107A3 (en) 1987-10-08 1990-04-18 Stichting REGA V.Z.W. Anti-hiv active 3'-fluoro-purine-2',3'-dideoxyribosides
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
HU221089B1 (en) * 1994-12-08 2002-08-28 Glaxo Group Ltd Rantes peptide derivates with antagonistic effect and uses thereof
WO1997025427A1 (en) * 1996-01-12 1997-07-17 Genetics Institute, Inc. Beta-chemokine, h1305 (mcp-2)
JP2000508527A (ja) * 1996-03-27 2000-07-11 アイコス コーポレイション 単球走化性タンパク質―５物質及び方法
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use

Also Published As

Publication number Publication date
ATE263242T1 (de) 2004-04-15
PT1021541E (pt) 2004-07-30
CN1148447C (zh) 2004-05-05
CN1145693C (zh) 2004-04-14
CN1271386A (zh) 2000-10-25
US20050201977A1 (en) 2005-09-15
CZ20001146A3 (cs) 2000-09-13
DK1439231T3 (da) 2007-11-05
EA003942B1 (ru) 2003-10-30
BG104266A (en) 2000-11-30
KR20010024214A (ko) 2001-03-26
SK4512000A3 (en) 2000-09-12
HU226414B1 (en) 2008-11-28
EP1021541A1 (en) 2000-07-26
HU226468B1 (en) 2008-12-29
HUP0003505A3 (en) 2005-11-28
HK1032426A1 (en) 2001-07-20
JP4230659B2 (ja) 2009-02-25
BG64679B1 (bg) 2005-11-30
CN1271385A (zh) 2000-10-25
EP0905241A1 (en) 1999-03-31
US20050164936A1 (en) 2005-07-28
EP0906954A1 (en) 1999-04-07
ATE264390T1 (de) 2004-04-15
EP1439231B1 (en) 2007-08-01
SK4502000A3 (en) 2000-09-12
PL339545A1 (en) 2000-12-18
HK1062637A1 (en) 2004-11-19
EP1439231A3 (en) 2004-12-22
AR013529A1 (es) 2000-12-27
AU750341B2 (en) 2002-07-18
DE69823218D1 (de) 2004-05-19
HK1032425A1 (en) 2001-07-20
US6977071B2 (en) 2005-12-20
US7326411B2 (en) 2008-02-05
BG64757B1 (bg) 2006-02-28
CZ299479B6 (cs) 2008-08-06
WO1999016877A1 (en) 1999-04-08
EP1439231A2 (en) 2004-07-21
NO20001609L (no) 2000-03-28
CA2304827A1 (en) 1999-04-08
AU750606B2 (en) 2002-07-25
UA73080C2 (en) 2005-06-15
BG104267A (en) 2000-11-30
US20050220790A1 (en) 2005-10-06
US20030124677A1 (en) 2003-07-03
DE69822856T2 (de) 2004-08-19
HUP0003563A2 (hu) 2001-02-28
DE69838188D1 (de) 2007-09-13
DE69823218T2 (de) 2004-08-26
US6905676B2 (en) 2005-06-14
JP4233214B2 (ja) 2009-03-04
US7338653B2 (en) 2008-03-04
ES2215324T3 (es) 2004-10-01
HUP0003563A3 (en) 2005-11-28
EE200000152A (et) 2001-02-15
KR20010024213A (ko) 2001-03-26
US20030119148A1 (en) 2003-06-26
EP0905240A1 (en) 1999-03-31
DE69838188T2 (de) 2007-11-22
KR100560275B1 (ko) 2006-03-10
PL197569B1 (pl) 2008-04-30
DK1019507T3 (da) 2004-07-19
EA200000379A1 (ru) 2000-10-30
WO1999016876A1 (en) 1999-04-08
CZ20001147A3 (cs) 2000-09-13
PT1439231E (pt) 2007-08-20
NO20001584L (no) 2000-03-27
ES2218860T3 (es) 2004-11-16
JP2001518297A (ja) 2001-10-16
AR013528A1 (es) 2000-12-27
NO20001584D0 (no) 2000-03-27
CZ299478B6 (cs) 2008-08-06
ES2287601T3 (es) 2007-12-16
HUP0003505A2 (hu) 2001-02-28
NZ503235A (en) 2002-08-28
DK1021541T3 (da) 2004-08-02
ZA988675B (en) 1999-11-24
CA2305017A1 (en) 1999-04-08
UA73081C2 (en) 2005-06-15
NZ503234A (en) 2002-06-28
NO20001609D0 (no) 2000-03-28
PL339559A1 (en) 2000-12-18
EP1019507A1 (en) 2000-07-19
SK286495B6 (sk) 2008-11-06
ZA988676B (en) 1999-12-03
IL135352A (en) 2006-08-20
CY1110927T1 (el) 2015-06-10
CN1490049A (zh) 2004-04-21
EE200000151A (et) 2001-02-15
JP2001518296A (ja) 2001-10-16
EP1021541B1 (en) 2004-04-14
IL135351A (en) 2006-08-20
AU9747498A (en) 1999-04-23
CN1233415C (zh) 2005-12-28
AU9442098A (en) 1999-04-23
PT1019507E (pt) 2004-06-30
EP1019507B1 (en) 2004-03-31
PL196427B1 (pl) 2008-01-31
BR9812394A (pt) 2000-09-12
EA003940B1 (ru) 2003-10-30
SK286439B6 (sk) 2008-10-07
EA200000378A1 (ru) 2000-10-30
NZ516027A (en) 2003-05-30
ATE368742T1 (de) 2007-08-15
KR100542934B1 (ko) 2006-01-11
DE69822856D1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
BR9812565A (pt) Amino terminalmente truncado rantes como antagonistas da quimiocina
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
BR9809655A (pt) Uso de derivados do ácido fumárico
BR0212897A (pt) Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
BR0109027A (pt) Peptìdios derivados de caseìna e usos dos mesmos em terapia
Nylander-Lundqvist et al. IL-1 beta activation in human epidermis.
BR0015506A (pt) Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
BR0309877A (pt) Peptìdeos estimuladores de tecido conectivo
ES2031804T3 (es) Derivado del activador de plasminogeno de tipo tisular.
DE3650358D1 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
DE69221486D1 (de) Bombesinanaloge
BRPI0415290A (pt) uso terapêutico de variantes de quimiocina
BR0013638A (pt) Novas moléculas semelhantes a interferon beta
BR0309238A (pt) Antagonistas de proteìnas mcp
HRP20030215B1 (en) Chemokine mutants in the tratment of multiple sclerosis
RU2002135669A (ru) Олигопептиды
BR9809457A (pt) Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia.
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
WO1999014322A3 (en) Allelic variant of human stat3
WO2002013845A3 (en) Inflammation related g-protein coupled receptor
DK0811068T3 (da) Humane DNase I varianter
ATE410516T1 (de) Varianten der humanen glycosylphosphatidylinositol-spezifischen phospholipase d und ihre verwendungen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM O ART. 13 DA LPI 9279/96).

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.